These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16778179)

  • 21. Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
    Gong L; Yang B; Xu M; Cheng B; Tang X; Zheng P; Jing Y; Wu GJ
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):69-77. PubMed ID: 24190701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
    Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
    Mortenson MM; Schlieman MG; Virudachalam S; Lara PN; Gandara DG; Davies AM; Bold RJ
    Lung Cancer; 2005 Aug; 49(2):163-70. PubMed ID: 16022909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
    Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
    Shi YY; Small GW; Orlowski RZ
    Breast Cancer Res Treat; 2006 Nov; 100(1):33-47. PubMed ID: 16807678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
    Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
    Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
    Dasmahapatra G; Lembersky D; Rahmani M; Kramer L; Friedberg J; Fisher RI; Dent P; Grant S
    Cancer Biol Ther; 2009 May; 8(9):808-19. PubMed ID: 19270531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting aurora kinases as therapy in multiple myeloma.
    Shi Y; Reiman T; Li W; Maxwell CA; Sen S; Pilarski L; Daniels TR; Penichet ML; Feldman R; Lichtenstein A
    Blood; 2007 May; 109(9):3915-21. PubMed ID: 17213289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
    Chen S; Blank JL; Peters T; Liu XJ; Rappoli DM; Pickard MD; Menon S; Yu J; Driscoll DL; Lingaraj T; Burkhardt AL; Chen W; Garcia K; Sappal DS; Gray J; Hales P; Leroy PJ; Ringeling J; Rabino C; Spelman JJ; Morgenstern JP; Lightcap ES
    Cancer Res; 2010 Jun; 70(11):4318-26. PubMed ID: 20460535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
    Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
    Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
    Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.